行情

CANF

CANF

灿菲特生物制药
AMEX

实时行情|Nasdaq Last Sale

2.200
-0.060
-2.65%
盘前: 2.220 +0.02 +0.91% 08:29 08/07 EDT
开盘
2.300
昨收
2.260
最高
2.320
最低
2.150
成交量
134.64万
成交额
--
52周最高
4.950
52周最低
1.080
市值
3,391.08万
市盈率(TTM)
-0.5663
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CANF价格均价为6.00,最高价位7.00,最低价为5.00。

EPS

CANF 新闻

更多
Can-Fite nearing start of Piclidenoson study in COVID-19
Seeking Alpha · 07/27 11:49
Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study
Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study
Business Wire · 07/27 11:00
Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today it has completed the
Benzinga · 07/20 11:10
Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds
Business Wire · 07/20 11:00
Can-Fite Announces $3.4 Million Registered Direct Offering
Business Wire · 07/06 13:00
Can-Fite plunges 10% on $3.4M direct offering
Seeking Alpha - Article · 07/06 12:38
Can-Fite Announces Final Data Analysis from Phase II NASH Study: Highly Significant and Sustained Reduction in Liver Fat Volume Throughout Study Period
Business Wire · 06/30 12:00
Can-Fite announces final data from mid-stage study of Namodenoson in NASH
Seeking Alpha - Article · 06/30 11:39

所属板块

生物技术和医学研究
-0.96%
制药与医学研究
-0.46%

热门股票

代码
价格
涨跌幅

CANF 简况

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
展开

微牛提供Can Fite Biopharma Ltd(AMEX-CANF)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CANF股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CANF股票基本功能。